Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines.
Xuemei XieJangsoon LeeJon A FusonHuey LiuToshiaki IwaseKyuson YunCori MargainDebasish TripathyNaoto Tada UenoPublished in: Biomedicines (2023)
Our data suggest a new strategy of combining eribulin with PI3K or mTOR inhibitors to treat TNBC.